These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24231729)

  • 1. mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions.
    Matsubara S; Ding Q; Miyazaki Y; Kuwahata T; Tsukasa K; Takao S
    Sci Rep; 2013 Nov; 3():3230. PubMed ID: 24231729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.
    Mueller MT; Hermann PC; Witthauer J; Rubio-Viqueira B; Leicht SF; Huber S; Ellwart JW; Mustafa M; Bartenstein P; D'Haese JG; Schoenberg MH; Berger F; Jauch KW; Hidalgo M; Heeschen C
    Gastroenterology; 2009 Sep; 137(3):1102-13. PubMed ID: 19501590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
    Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
    PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition.
    Miyazaki Y; Matsubara S; Ding Q; Tsukasa K; Yoshimitsu M; Kosai K; Takao S
    Mol Cancer; 2016 Jun; 15(1):49. PubMed ID: 27349387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance.
    Huang FT; Zhuan-Sun YX; Zhuang YY; Wei SL; Tang J; Chen WB; Zhang SN
    Int J Oncol; 2012 Nov; 41(5):1707-14. PubMed ID: 22923052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR activation in immature cells of primary nasopharyngeal carcinoma and anti-tumor effect of rapamycin in vitro and in vivo.
    Yang C; Peng J; Jiang W; Zhang Y; Chen X; Wu X; Zhu Y; Zhang H; Chen J; Wang J; Cho WC; Jin K
    Cancer Lett; 2013 Dec; 341(2):186-94. PubMed ID: 23933173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
    Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
    Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
    Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
    J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition.
    Matsubara S; Tsukasa K; Kuwahata T; Takao S
    Hum Cell; 2020 Oct; 33(4):1197-1203. PubMed ID: 32851605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.
    Sharma N; Nanta R; Sharma J; Gunewardena S; Singh KP; Shankar S; Srivastava RK
    Oncotarget; 2015 Oct; 6(31):32039-60. PubMed ID: 26451606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation.
    Okada M; Shibuya K; Sato A; Seino S; Suzuki S; Seino M; Kitanaka C
    Oncotarget; 2014 Jul; 5(13):5100-12. PubMed ID: 24947996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties.
    Luo G; Long J; Cui X; Xiao Z; Liu Z; Shi S; Liu L; Liu C; Xu J; Li M; Yu X
    Int J Oncol; 2013 Mar; 42(3):979-84. PubMed ID: 23338123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD133+ cells from medulloblastoma and PNET cell lines are more resistant to cyclopamine inhibition of the sonic hedgehog signaling pathway than CD133- cells.
    Enguita-Germán M; Schiapparelli P; Rey JA; Castresana JS
    Tumour Biol; 2010 Oct; 31(5):381-90. PubMed ID: 20480407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways.
    Wang JY; Chang CC; Chiang CC; Chen WM; Hung SC
    J Cell Biochem; 2012 May; 113(5):1733-43. PubMed ID: 22213051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver.
    Spormann L; Rennert C; Kolbe E; Ott F; Lossius C; Lehmann R; Gebhardt R; Berg T; Matz-Soja M
    Cells; 2020 Jul; 9(8):. PubMed ID: 32751882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide.
    Banerjee S; Nomura A; Sangwan V; Chugh R; Dudeja V; Vickers SM; Saluja A
    Clin Cancer Res; 2014 May; 20(9):2388-99. PubMed ID: 24634377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finding and killing the CRABs of pancreatic cancer.
    Caldwell ME; Tuveson DA
    Gastroenterology; 2009 Sep; 137(3):782-5. PubMed ID: 19643193
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.
    Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH
    J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer.
    Nomura A; McGinn O; Dudeja V; Sangwan V; Saluja AK; Banerjee S
    Mol Cancer; 2015 Nov; 14():200. PubMed ID: 26597727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer.
    Zuo M; Rashid A; Churi C; Vauthey JN; Chang P; Li Y; Hung MC; Li D; Javle M
    Br J Cancer; 2015 Mar; 112(6):1042-51. PubMed ID: 25742482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.